Mirvetuximab: Practice Changing for Some Ovarian Cancers Mirvetuximab: Practice Changing for Some Ovarian Cancers
Response rates were superior to those seen with other single agents in patients with platinum-resistant disease and tumors positive for folate receptor alpha.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Hematology | Ovarian Cancer | Ovaries